BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

...Celgene Corp. acquired in 2015; former Receptos President and CEO Faheem Hasnain is Gossamer’s chairman. Receptos’...
BioCentury | May 6, 2020
Regulation

Extended review of Bristol’s CAR T leaves little daylight for CVR from Celgene deal

...to treat multiple sclerosis. That program was the key to Celgene’s $7.2 billion takeout of Receptos Inc....
BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

...neurology community to inform launch timing." Zeposia was the key to Celgene’s 2015 takeout of Receptos Inc....
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...seeded autoimmune and inflammation play Gossamer Bio Inc. (NASDAQ:GOSS), whose management includes former executives from Receptos Inc....
...Both of those companies’ teams had been through company exits before reuniting. Celgene Corp. acquired Receptos...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...million in February at a $1 billion valuation. Led by the former management team behind Receptos Inc....
BioCentury | Feb 13, 2019
Financial News

Gossamer Bio prices $276M IPO

...on its first day of trading Feb. 8. Launched officially just 13 months ago by ex-Receptos Inc....
...Gossamer's shareholders include Arch Venture Partners, Omega Funds and Hillhouse Capital. Celgene Corp. (NASDAQ:CELG) acquired Receptos...
BioCentury | Feb 8, 2019
Financial News

Gossamer Bio prices $276M IPO

...priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc....
...Gossamer's shareholders include Arch Venture Partners, Omega Funds and Hillhouse Capital. Celgene Corp. (NASDAQ:CELG) acquired Receptos...
BioCentury | Jan 25, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

...treat chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, respectively. Gossamer was launched by ex-Receptos Inc....
BioCentury | Jan 24, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

...treat chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, respectively. Gossamer was launched by ex-Receptos Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...S1P1; EDG1) and S1PR5 (EDG8; S1P5) inhibitor. The compound, gained via Celgene’s 2015 acquisition of Receptos Inc....
Items per page:
1 - 10 of 156
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

...Celgene Corp. acquired in 2015; former Receptos President and CEO Faheem Hasnain is Gossamer’s chairman. Receptos’...
BioCentury | May 6, 2020
Regulation

Extended review of Bristol’s CAR T leaves little daylight for CVR from Celgene deal

...to treat multiple sclerosis. That program was the key to Celgene’s $7.2 billion takeout of Receptos Inc....
BioCentury | Mar 26, 2020
Regulation

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

...neurology community to inform launch timing." Zeposia was the key to Celgene’s 2015 takeout of Receptos Inc....
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...seeded autoimmune and inflammation play Gossamer Bio Inc. (NASDAQ:GOSS), whose management includes former executives from Receptos Inc....
...Both of those companies’ teams had been through company exits before reuniting. Celgene Corp. acquired Receptos...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...million in February at a $1 billion valuation. Led by the former management team behind Receptos Inc....
BioCentury | Feb 13, 2019
Financial News

Gossamer Bio prices $276M IPO

...on its first day of trading Feb. 8. Launched officially just 13 months ago by ex-Receptos Inc....
...Gossamer's shareholders include Arch Venture Partners, Omega Funds and Hillhouse Capital. Celgene Corp. (NASDAQ:CELG) acquired Receptos...
BioCentury | Feb 8, 2019
Financial News

Gossamer Bio prices $276M IPO

...priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc....
...Gossamer's shareholders include Arch Venture Partners, Omega Funds and Hillhouse Capital. Celgene Corp. (NASDAQ:CELG) acquired Receptos...
BioCentury | Jan 25, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

...treat chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, respectively. Gossamer was launched by ex-Receptos Inc....
BioCentury | Jan 24, 2019
Financial News

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

...treat chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, respectively. Gossamer was launched by ex-Receptos Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...S1P1; EDG1) and S1PR5 (EDG8; S1P5) inhibitor. The compound, gained via Celgene’s 2015 acquisition of Receptos Inc....
Items per page:
1 - 10 of 156